Director, Clinical Immunology

OMass Therapeutics is a biotechnology company based in Oxford discovering medicines against highly- validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. OMass is advancing a pipeline of small-molecule therapeutics